Phase 2Not yet recruitingNCT07614412

SHIELD-T1D: Shingrix and semaglutide for beta-cell preservation

What this study tests

Saudi phase 2 randomized trial testing Shingrix, semaglutide, their combination, or placebo in adults with recent-onset type 1 diabetes to assess whether immune adjuvant plus GLP-1 support preserves C-peptide.

Editorial review: 2026-08-27.

Registry checked: 2026-09-17. Registry’s own update: 2026-05-29.

Most recent recorded citation date: 2026-05-29. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Evidence at a glance

Who can enter the study?: Adults aged 18-50 with recent-onset type 1 diabetes. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
Reported benefit and results: No results posted yet.Read the result sources and their limitations →
Important harms: Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
Research access and approval: Study regions: Other regions. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
What remains uncertain?: Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.

Research status alone does not establish approval, clinical benefit or local availability.

Primary endpoints

Change in 2-hour stimulated C-peptide AUC during mixed-meal tolerance test at 12 months

The full picture

This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.

Sources

[1]
SHIELD-T1D Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes · Trial registry · 2026-05-29